GlassScriptPhysician profile
Ahmed Baig
NPI 1164538989
$4,881.02
in general payments reported to CMS, 2019-2025
21 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.47 · 2020: $16.79 · 2021: $322 · 2022: $662 · 2023: $1,143 · 2024: $1,371 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,829.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,775.23 | 2021-2025 | Caplyta |
| Alkermes, INC. | $609.50 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $523.75 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $420.91 | 2023 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $321.00 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $218.10 | 2022-2025 | Spravato |
| Livanova USA, INC. | $134.22 | 2023-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Abbvie INC. | $133.40 | 2024-2025 | |
| Noven Pharmaceuticals, INC. | $114.19 | 2023 | Xelstrym |
| Otsuka America Pharmaceutical, INC. | $112.67 | 2021-2025 | Abilify Maintena, Abilify Asimtufii |
| Bausch Health US, LLC | $94.26 | 2021-2025 | Aplenzin |
| Noven Therapeutics, LLC | $76.78 | 2024 | Xelstrym, Secuado |
| Tris Pharma INC | $75.49 | 2022-2024 | Dyanavel Xr |
| Corium, LLC | $67.99 | 2021-2022 | |
| Almatica Pharma LLC | $65.34 | 2024-2025 | Loreev Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $54.12 | 2022 | |
| Mannkind Corporation | $24.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.81 | 2021 | |
| Novo Nordisk INC | $16.79 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.08 | 2019 | |
| Pfizer INC. | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.